BTIG Reiterates Buy on Spyre Therapeutics, Maintains $70 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.2%

Neg 0% Neu 87.2% Pos 0%

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $70 price target.

Comments

No comments yet. Be the first!